Condition
Central Nervous System Neoplasms, Primary
Total Trials
3
Recruiting
1
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 1 (2)
Trial Status
Recruiting1
Active Not Recruiting1
Withdrawn1
Clinical Trials (3)
Showing 3 of 3 trials
NCT03911388Phase 1Recruiting
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
NCT04446962Phase 1Active Not Recruiting
LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV)
NCT03530605Not ApplicableWithdrawnPrimary
Use of Optune TTF With Radiation as an Alternative for Elderly Patients With Primary CNS Lymphoma
Showing all 3 trials